Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 35661P100 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Roche Holdings, Inc.
13G
|
17.4% |
9/1/2026
Event 7/20/2026
|
||
| Roche Holdings, Inc. | 17.4% | |||
| Roche Finance Ltd | 17.4% | |||
| Roche Holding Ltd | 17.4% | |||
|
RA Capital Management, L.P.
13D/A
|
14.3% |
7/22/2026
Event 7/20/2026
|
||
| RA Capital Management, L.P. | 14.3% | |||
| Peter Kolchinsky | 14.3% | |||
| Rajeev Shah | 14.3% | |||
| RA Capital Healthcare Fund, L.P. | 11.4% | |||
|
Perceptive Advisors LLC
13G
|
10.1% |
7/23/2026
Event 7/20/2026
|
||
| Perceptive Advisors LLC | 10.1% | |||
| Joseph Edelman | 10.1% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 10.1% | |||
|
ADAR1 Capital Management, LLC
13G/A
|
8.3% |
8/14/2026
Event 6/30/2026
|
||
| ADAR1 Capital Management, LLC | 8.3% | |||
| ADAR1 Capital Management GP, LLC | 6.1% | |||
| Daniel Schneeberger | 8.3% | |||
|
AH Bio Fund I, L.P.
13G
|
5.2% |
7/27/2026
Event 7/20/2026
|
||
| AH Bio Fund I, L.P. | 3.1% | |||
| AH Equity Partners Bio I, L.L.C. | 3.1% | |||
| Andreessen Horowitz LSV Fund II, L.P. | 1.0% | |||
| AH Equity Partners LSV II, L.L.C. | 1.0% | |||
| CLF Partners, LP | 0% | |||
| AH Equity Partners V, L.L.C. | 0% | |||
| AH Parallel Fund IV, L.P. | 1.1% | |||
| AH Equity Partners IV (Parallel), L.L.C. | 1.1% | |||
| Marc L. Andreessen | 5.2% | |||
| Benjamin A. Horowitz | 5.2% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (1) | ||||
| Highbridge Capital Management, LLC 13G | 0% |
8/14/2026
Event 6/30/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|